Avadel Pharma (AVDL) Tops Q3 EPS by 5c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $50.03 million versus the consensus estimate of $48.44 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Musalem: strong growth and investment influencing bond market - CNBC
• LivePerson adjourns stockholder vote on SoundHound AI merger to Sept. 2
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance